169 related articles for article (PubMed ID: 18413841)
1. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
[TBL] [Abstract][Full Text] [Related]
2. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R
Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625
[TBL] [Abstract][Full Text] [Related]
3. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Blake S; Hughes TP; Mayrhofer G; Lyons AB
Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
[TBL] [Abstract][Full Text] [Related]
4. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
Wölfl M; Schwinn S; Yoo YE; Reß ML; Braun M; Chopra M; Schreiber SC; Ayala VI; Ohlen C; Eyrich M; Beilhack A; Schlegel PG
Blood; 2013 Aug; 122(7):1203-13. PubMed ID: 23836556
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
Hassold N; Seystahl K; Kempf K; Urlaub D; Zekl M; Einsele H; Watzl C; Wischhusen J; Seggewiss-Bernhardt R
Int J Cancer; 2012 Sep; 131(6):E916-27. PubMed ID: 22419518
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Greiner J; Götz M; Guillaume P; Döhner H; Bunjes D; Schmitt M
Exp Hematol; 2008 Oct; 36(10):1297-308. PubMed ID: 18619726
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Götz M; Döhner H; Bunjes D; Schmitt M
Br J Haematol; 2009 Jan; 144(2):195-205. PubMed ID: 19016717
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Fraser CK; Blake SJ; Diener KR; Lyons AB; Brown MP; Hughes TP; Hayball JD
Exp Hematol; 2009 Feb; 37(2):256-65. PubMed ID: 19056158
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Harrington P; Dillon R; Radia D; Rousselot P; McLornan DP; Ong M; Green A; Verde A; Hussain F; Raj K; Kordasti S; Harrison C; De Lavallade H
Haematologica; 2023 Jun; 108(6):1555-1566. PubMed ID: 36700403
[TBL] [Abstract][Full Text] [Related]
13. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function.
Wehrstedt S; Kubis J; Zimmermann A; Bruns H; Mayer D; Grieshober M; Stenger S
Eur J Immunol; 2018 Nov; 48(11):1892-1903. PubMed ID: 30242834
[TBL] [Abstract][Full Text] [Related]
15. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
16. The targeting of human and mouse B lymphocytes by dasatinib.
Oksvold MP; Duyvestyn JM; Dagger SA; Taylor SJ; Forfang L; Myklebust JH; Smeland EB; Langdon WY
Exp Hematol; 2015 May; 43(5):352-363.e4. PubMed ID: 25641047
[TBL] [Abstract][Full Text] [Related]
17. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3.
Nerreter T; Köchel C; Jesper D; Eichelbrönner I; Putz E; Einsele H; Seggewiss-Bernhardt R
Exp Hematol; 2014 Sep; 42(9):773-82.e1-3. PubMed ID: 24882272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]